Stay updated on Pembrolizumab vs Standard Therapy in MSI-H/dMMR Stage IV CRC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Standard Therapy in MSI-H/dMMR Stage IV CRC Clinical Trial page.

Latest updates to the Pembrolizumab vs Standard Therapy in MSI-H/dMMR Stage IV CRC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe revision tag in the study record history was updated to v3.6.6, signaling a newer version of the page. It is a metadata update and does not alter the trial data or displayed content.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedA new revision tag (v3.6.5) was added to the history. The References section and the previous revision (v3.6.4) were removed.SummaryDifference0.1%

- Check51 days agoChange DetectedThe record history now shows a new latest revision labeled v3.6.4, updating the page from the previous v3.6.3; this reflects a maintenance/versioning update rather than changes to study content.SummaryDifference0.0%

- Check73 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, signaling a newer version of the page. This metadata change does not modify study data or user-facing content beyond the version label.SummaryDifference0.0%

- Check80 days agoChange DetectedA new site revision (v3.6.2) was added to the record history and the previous revision (v3.6.0) was removed, reflecting a platform update in the page history.SummaryDifference0.0%

- Check94 days agoChange DetectedNo longer looking for participants indicates recruitment has ended. The history adds Revision: v3.6.0 and removes Revision: v3.5.5 from the record.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab vs Standard Therapy in MSI-H/dMMR Stage IV CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Therapy in MSI-H/dMMR Stage IV CRC Clinical Trial page.